Jeffrey A. Hubbell Ph.d.
United States of America
Prof. Jeffrey A. Hubbell, Ph.D., is a Co-Founder and Office of The Chief Scientific Officer at Anokion SA. Prof. Hubbell co-founded Kuros Biosciences AG in 2002 and served as its Chief Scientific Officer. He serves as a Consultant or a Scientific Advisor to several other entrepreneurial enterprises. Prof. Hubbell founded two start-up companies in addition to Kuros, namely Focal, Inc. and InfiMed Therapeutics. He is a Professor of Biomedical Engineering and a Director of the Institute of Bioengineering at the École Polytechnique Fédérale de Lausanne (EPFL). Prof. Hubbell is also a Professor of the Institute of Chemical Sciences and Engineering, EPFL. He was a Professor of Biomedical Engineering and a Director of the Institute for Biomedical Engineering at the Swiss Federal Institute of Technology and the University of Zurich. Prof. Hubbell served as an Assistant and Associate Professor of Chemical Engineering at the University of Texas in Austin and a Professor of Chemical Engineering at the California Institute of Technology, before moving to Switzerland in 1997. His academic research focuses on novel biomaterials for surgery, for drug delivery, and for tissue engineering, each with a particular focus on tissue regeneration and reconstruction. He serves as a Member of Advisory Board. Prof. Hubbell serves as a Director of Anokion SA. He serves as a Member of Scientific Advisory Board of Xeltis AG. Prof. Hubbell serves as a Scientific Advisor of NeoMed. He served as a Member of Scientific Advisory Board of ViaCyte, Inc. (formerly Novocell, Inc.). Prof. Hubbell served as a Director of Novartis Venture Funds and Kuros Biosciences AG. He is author of nearly 100 scientific works and more than 25 issued US patents. He is a fellow of the American Institute of Medical and Biological Engineering. Prof. Hubbell holds a Ph.D. degree.
He is interested in Pharma Sciences.